Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-08-23

Clinical Trial Update: Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 trial update reports on the efficacy, safety, and tolerability of CEP-701 in patients with severe psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CEP-701 (lestaurtinib)

Snippet

Sponsor: Cephalon | Conditions: Psoriasis | Phase 2 | Status: COMPLETED